Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up with demand for the blockbuster GLP-1 drugs.

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication "off-label" for weight loss, as is permissible by the FDA.

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.

In general, when a person prepares for a surgery, the guidance is to fast before going under anesthesia– but for patients, on gGLP-1's there may still be gastric juices, in the stomach, since the drugs slow down the process of emptying the stomach.